| Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer DE Rathkopf, MJ Morris, JJ Fox, DC Danila, SF Slovin, JH Hager, PJ Rix, ... Journal of clinical oncology 31 (28), 3525-3530, 2013 | 290 | 2013 |
| A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index D Ulmert, R Kaboteh, JJ Fox, C Savage, MJ Evans, H Lilja, ... European urology 62 (1), 78-84, 2012 | 217 | 2012 |
| Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer ER Dennis, X Jia, IS Mezheritskiy, RD Stephenson, H Schoder, JJ Fox, ... Journal of Clinical Oncology 30 (5), 519, 2012 | 214 | 2012 |
| Prognostic Value of Baseline [18F] Fluorodeoxyglucose Positron Emission Tomography and 99mTc-MDP Bone Scan in Progressing Metastatic Prostate Cancer GSP Meirelles, H Schöder, GC Ravizzini, M Gönen, JJ Fox, J Humm, ... Clinical Cancer Research 16 (24), 6093-6099, 2010 | 154 | 2010 |
| The effect of posttherapy 131I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer RK Grewal, RM Tuttle, J Fox, S Borkar, JF Chou, M Gonen, HW Strauss, ... Journal of Nuclear Medicine 51 (9), 1361-1367, 2010 | 144 | 2010 |
| Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall … HA Vargas, C Wassberg, JJ Fox, A Wibmer, DA Goldman, D Kuk, ... Radiology 271 (1), 220-229, 2014 | 107 | 2014 |
| Positron emission tomography/computed tomography–based assessments of androgen receptor expression and glycolytic activity as a prognostic biomarker for metastatic castration … JJ Fox, SC Gavane, E Blanc-Autran, S Nehmeh, M Gönen, B Beattie, ... JAMA oncology 4 (2), 217-224, 2018 | 99 | 2018 |
| Pediatric Bone Sarcoma: Diagnostic Performance of 18F-FDG PET/CT Versus Conventional Imaging for Initial Staging and Follow-Up N Quartuccio, J Fox, D Kuk, LH Wexler, S Baldari, A Cistaro, H Schöder American Journal of Roentgenology 204 (1), 153-160, 2015 | 96 | 2015 |
| Molecular imaging of prostate cancer JJ Fox, H Schöder, SM Larson Current opinion in urology 22 (4), 320-327, 2012 | 71 | 2012 |
| Predicting outcome in patients with rhabdomyosarcoma: Role of [18F] fluorodeoxyglucose positron emission tomography DL Casey, LH Wexler, JJ Fox, KV Dharmarajan, H Schoder, AN Price, ... International Journal of Radiation Oncology* Biology* Physics 90 (5), 1136-1142, 2014 | 65 | 2014 |
| Noncontrast perfusion single-photon emission CT/CT scanning: a new test for the expedited, high-accuracy diagnosis of acute pulmonary embolism Y Lu, A Lorenzoni, JJ Fox, J Rademaker, N Vander Els, RK Grewal, ... Chest 145 (5), 1079-1088, 2014 | 64 | 2014 |
| Positron emission tomography (PET) evaluation after initial chemotherapy and radiation therapy predicts local control in rhabdomyosarcoma KV Dharmarajan, LH Wexler, S Gavane, JJ Fox, H Schoder, AK Tom, ... International Journal of Radiation Oncology* Biology* Physics 84 (4), 996-1002, 2012 | 55 | 2012 |
| Radiological impact of the use of calcium hydroxylapatite dermal fillers JN Feeney, JJ Fox, T Akhurst Clinical radiology 64 (9), 897-902, 2009 | 54 | 2009 |
| Practical approach for comparative analysis of multilesion molecular imaging using a semiautomated program for PET/CT JJ Fox, E Autran-Blanc, MJ Morris, S Gavane, S Nehmeh, A Van Nuffel, ... Journal of Nuclear Medicine 52 (11), 1727-1732, 2011 | 50 | 2011 |
| Developing imaging strategies for castration resistant prostate cancer JJ Fox, MJ Morris, SM Larson, H Schöder, HI Scher Acta Oncologica 50 (sup1), 39-48, 2011 | 47 | 2011 |
| Imaging patients with metastatic castration-resistant prostate cancer using 89Zr-DFO-MSTP2109A anti-STEAP1 antibody JA Carrasquillo, BM Fine, N Pandit-Taskar, SM Larson, SE Fleming, ... Journal of Nuclear Medicine 60 (11), 1517-1523, 2019 | 40 | 2019 |
| One step closer to imaging vulnerable plaque in the coronary arteries JJ Fox, HW Strauss Journal of Nuclear Medicine 50 (4), 497-500, 2009 | 39 | 2009 |
| Immunomodulatory activity of a colony-stimulating factor-1 receptor inhibitor in patients with advanced refractory breast or prostate cancer: a phase I study KA Autio, CA Klebanoff, D Schaer, JSW Kauh, SF Slovin, M Adamow, ... Clinical Cancer Research 26 (21), 5609-5620, 2020 | 37 | 2020 |
| Dickkopf-1 can lead to immune evasion in metastatic castration-resistant prostate cancer DR Wise, JA Schneider, J Armenia, VA Febles, B McLaughlin, R Brennan, ... JCO precision oncology 4, 1167-1179, 2020 | 37 | 2020 |
| Pharmacokinetics and Biodistribution of a [89Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients JA O’Donoghue, DC Danila, N Pandit-Taskar, V Beylergil, SM Cheal, ... Molecular pharmaceutics 16 (7), 3083-3090, 2019 | 33 | 2019 |
